Funding for this research was provided by:
Fonds Léon Fredericq
Fonds De La Recherche Scientifique - FNRS
the Neurological Foundation of New Zealand
Received: 12 January 2021
Accepted: 21 March 2021
First Online: 1 April 2021
: Human GBM samples were obtained in collaboration with the Neurosurgical department of the academic hospital (CHU of Liège, Liège, Belgium) in accordance with the research protocol (Belgian number: B707201420125) with approval from the ethical committee of the CHU of Liège. Additional GBM and non-cancerous brain tissues from donors were obtained from the Biobank of the Hospital and the University of Liège (BHUL, Uliège, Liège, Belgium) according to the protocol approved on the 12<sup>th</sup> of July 2016 by the Ethical Committee of the CHU of Liège. All patients gave informed consent before the study started. Adult (P40) female <i>Nu/Nu Nude</i> (immuno-deficient) mice (Crl:NU-<i>Foxn1</i><sup><i>nu</i></sup>) obtained from Charles River Laboratories® (Wilmington, UK) were cared for in accordance with the Declaration of Helsinki, following the guidelines of the Belgium Ministry of Agriculture in agreement with the European Commission Laboratory Animal Care and Use Regulation (86/609/CEE, CE of J nL358, 18 December 1986). Animals were handled as approved by local ethical committee (2157).
: Not applicable.
: The authors declare that they have no competing interests.